Overall and patient-level comparative effectiveness of dimethyl fumarate and fingolimod: A precision medicine application to the Observatoire Français de la Sclérose en Plaques registry.

Gabrielle SimoneauXiaotong JiangFabien RollotLu TianMassimiliano CopettiMatthieu GuéryMarta RuizBertrand AudoinCarl de MoorFabio Pellegrininull null

Published in: Multiple sclerosis journal - experimental, translational and clinical (2022)

These findings substantiated the similar effectiveness and different discontinuation profiles for dimethyl fumarate and fingolimod as a second-line therapy for relapsing-remitting multiple sclerosis, with no significant effect heterogeneity observed.

Keyphrases

multiple sclerosis
white matter
randomized controlled trial
case report
systematic review
single cell